INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer

Sponsor
Guangzhou Ruixin Biotechnological Co., LTD
Study ID
NCT06747832
Phase
EARLY_PHASE1
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • iNK cells — DRUG
    Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.

Study Details

This is a clinical study on the use of iNK cells for the treatment of small cell lung cancer.

Key Dates

First listed
Dec 24, 2024
Start date
Dec 15, 2024
Status verified
Dec 2024
Primary completion
Jun 14, 2026
Completion
Dec 14, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: iNK Cell therapy group
    Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.

Primary Outcome Measure

Number of Participants with Adverse Event (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0 [ Time Frame: 12 months ]

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies